00:43 , Jan 13, 2018 |  BioCentury  |  Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market in...
23:29 , Oct 6, 2017 |  BioCentury  |  Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
17:31 , Sep 15, 2017 |  BC Week In Review  |  Financial News

ADial proposes $16.1M IPO

On Sept. 6, alcohol abuse company ADial Pharmaceuticals LLC (Charlottesville, Va.) proposed to raise $16.1 million through the sale of 1.4 million shares in an IPO on NASDAQ underwritten by Aegis Capital Corp. ADial Pharmaceuticals LLC,...
22:06 , Apr 28, 2017 |  BioCentury  |  Emerging Company Profile

Cutting cravings

The former executive team from CV Therapeutics Inc. are treading familiar ground with an addiction program licensed from Gilead Sciences Inc. Newco Amygdala Neurosciences Inc. aims to develop ANS-6673 to treat substance abuse disorders currently...
08:00 , Nov 6, 2014 |  BC Innovations  |  Tools & Techniques

AD goes 3D

A 3D cell-based model that encapsulates the two hallmark features of Alzheimer's disease-neurofibrillary tangles and b-amyloid plaques-has been created by a team at Massachusetts General Hospital to help screen compounds for the disease.1Although the system...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Clinical News

AD02: Phase II data

Affiris' AD02 performed worse than placebo in a double-blind, international Phase II trial in 332 patients with early stage AD. Specifically, Affiris said AD02 missed the primary endpoint of improving composite ADAS-Cog and ADCS-ADL score...
00:51 , Jun 5, 2014 |  BC Extra  |  Top Story

Affiris claims disease modification with Alzheimer's placebo

Affiris AG (Vienna, Austria) said the placebo in its Phase II trial of its AD02 vaccine against beta amyloid "is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

Adial, Cato BioVentures deal

ADial and VC firm Cato entered a deal under which the VC will invest $1.8 million in ADial in exchange for Cato's affiliate Cato Research Ltd. serving as ADial's preferred CRO for clinical trials...